[1]Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2): 115-132.
[2]陈鸿杰, 王民三.醋酸阿比特龙治疗去势抵抗性前列腺癌的研究进展[J].国际泌尿系统杂志, 2015, 35(3): 437-439.
[3]周爱萍,房虹,李长岭,等. 去势抗拒前列腺癌治疗新药醋酸阿比特龙[J]. 中国新药杂志,2013,22(17):1998-2001.
[4]Caffo O, Veccia A, Kinspergher S,et al. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review[J]. Future Oncol,2018, 14(5):431-442.
[5]吴开杰,介评.New England Journal of Medicine:阿比特龙在转移性激素敏感性前列腺癌中的应用---LATITUDE试验中期结果发布[J]. 现代泌尿外科杂志, 22 (8) :630-630.
[6]孙颖浩,杨悦.前列腺癌内分泌治疗的现状与展望[J].实用医院临床杂志, 2017 , 14 (6) :1-4.
[7]刘琪,刘明,朱刚,等. 转移性去势抵抗性前列腺癌药物治疗进展[J]. 现代泌尿外科杂志,2014,19(9):625-627.
[8]Fizazi K, Scher HI, Molina A. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol,2012,13(10):983-392.
[9]Draft Guidance on Abiraterone Acetate, FDA[DB/OL].https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM333001.pdf Accessed Jan 2016
[10]Inoue K, Shishido A, Vaccaro N, et al.Pharmacokinetics of abiraterone in healthy Japanese men:dose-proportionality and effect of food timing[J]. Cancer Chemother Pharmacol, 2015, 75(1):49-58.
[11]Chi KN,Spratlin J,Kollmannsberger C,et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer[J]. J Clini Pharma, 2015, 55(12): 1406-1414.
[12]Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer[J]. Steroids, 2015 , 95 :80-87.
[13]EMA/CHMP/542871 (2011) Assessment report for Zytiga procedure no.: EMEA/H/C/002321[R]. Assessment, vol. 44.
[14]Geboers S, Stappaerts J, Mols R, et al. The effect of food on the intraluminal behavior of abiraterone acetate in man[J]. J Pharm Sci, 2015,105(9):2974-2981.
[15]王晶,阳国平,黄洁,等, 醋酸阿比特龙片在中国健康受试者的药代动力学和生物等效性研究[J]. 中国临床药理学杂志, 2018,34(16): 1989-1992. |